OncoMatch/Clinical Trials/NCT06063681
A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
Is NCT06063681 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including SR-8541A and Immune checkpoint inhibitor (ICI) for advanced / metastatic solid tumor.
Treatment: SR-8541A · Immune checkpoint inhibitor (ICI) — This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint inhibitor (ICI) in subjects with solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer treatment
Prior systemic anti-cancer treatment including other investigational agents, surgery, or radiation within 28 days or 5 half-lives, whichever is less
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Cardiac function
No history of documented congestive heart failure (NYHA class II-IV); no unstable angina; no poorly controlled hypertension; no clinically significant valvular heart disease; no high-risk uncontrolled arrhythmias (including sustained ventricular tachycardia); no myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack within the last 6 months; no Canadian Cardiovascular Society angina class > 2; Troponin I ≤ ULN; BP - Systolic 95-160 mmHg and diastolic ≤ 100 mmHg; Resting HR ≤ 100 BPM; QTcF < 470 ms; LVEF ≥ 50%
Adequate hematologic, renal and hepatic function [required]. Cardiac exclusion criteria: history of documented congestive heart failure (NYHA class II-IV); unstable angina; poorly controlled hypertension; clinically significant valvular heart disease; high-risk uncontrolled arrhythmias (including sustained ventricular tachycardia); myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack within the last 6 months, or Canadian Cardiovascular Society angina class > 2; Troponin I > ULN; BP - Systolic < 95 mmHg or > 160 mmHg or diastolic > 100 mmHg; Resting HR > 100 BPM; QTcF ≥ 470 ms; LVEF < 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify